Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. milk yield
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Milk Yield Articles & Analysis

11 news found

More than muscles: Sports nutrition evolves

More than muscles: Sports nutrition evolves

Ingredients for muscle mass and post-workout recovery remain mainstays in sports nutrition, but the category is evolving and broadening. Ingredient examples are phospholipids for cognition and probiotic cultures for digestive health. “It’s very well-known that health is increasingly perceived holistically by consumers, especially younger demographics,” said Paige Wilkinson, ...

ByNuritas Ltd.


Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- Alnylam ...

ByAlnylam Pharmaceuticals, Inc.


Annual General Meeting of Infant Bacterial Therapeutics

Annual General Meeting of Infant Bacterial Therapeutics

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet; that no dividend is made; discharge from liability granted to Board members and the managing director, that the Board shall consist of ...

ByInfant Bacterial Therapeutics AB


Infant Bacterial Therapeutics publishes Annual Report for 2021

Infant Bacterial Therapeutics publishes Annual Report for 2021

Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media – Financial Reports” and is available in printed form for those that have requested. A copy can be requested by contacting IBT’s office via info@ibtherapeutics.com. About Infant ...

ByInfant Bacterial Therapeutics AB


CD BioGlyco Introduces HMOs Separation Service for Glycobiology Study

CD BioGlyco Introduces HMOs Separation Service for Glycobiology Study

CD BioGlyco, a biotechnology company that provides a full range of glycobiology-related products, analysis, custom synthesis and design to customers worldwide, recently introduced its HMOs separation and analysis services for the healthcare industry. Human milk is the best food for newborns and developing infants, and its unique function is irreplaceable by other dairy products. Human milk ...

ByCD BioGlyco.


Recruitment of the smallest infants in the Connection study paused

Recruitment of the smallest infants in the Connection study paused

IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per ...

ByInfant Bacterial Therapeutics AB


Infant Bacterial Therapeutics receives additional patent protection in China

Infant Bacterial Therapeutics receives additional patent protection in China

Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid bacteria, which protects formulations of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of ...

ByInfant Bacterial Therapeutics AB


New study reports activated B. infantis EVC001 feeding substantially reduces enteric inflammation, diaper rash and antibiotic use in preterm infants

New study reports activated B. infantis EVC001 feeding substantially reduces enteric inflammation, diaper rash and antibiotic use in preterm infants

“This study provides compelling evidence that feeding B. infantis EVC001 to preterm infants, along with human milk, yields meaningful reduction in gut dysbiosis, antibiotic resistant gene abundance and enteric inflammation – all leading health indicators that are linked to key health ...

ByEvolve BioSystems, Inc.


Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer

Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer

Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion diagnostic (CDx) that will utilize Thermo Fisher's next-generation sequencing (NGS)-based Oncomine Dx Target Test. The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


Organic valley and Gundersen health system break ground on Cashton greens wind farm, Wisconsin`s first community wind project

Organic valley and Gundersen health system break ground on Cashton greens wind farm, Wisconsin`s first community wind project

Organic Valley, the nation’s largest cooperative of organic farmers and a leading organic brand, and Gundersen Health System today announced construction has begun on the Cashton Greens Wind Farm, Wisconsin’s first community wind project. This collaborative project will feature two wind turbines expected to generate nearly 5 megawatts of energy for Cashton’s power ...

ByCSRwire - Corporate Social Responsibility Newswire


Drug Resistant Bacteria Found in Nation’s Meat and Poultry

Drug Resistant Bacteria Found in Nation’s Meat and Poultry

Cinnaminson, NJ, May 2nd, 2011 Last month it was reported that a new study discovered that the bacteria, Staphylococcus aureus, is found widely in the nation’s meat and poultry. The study found that 47% of the 136 samples taken from 26 retail stores in 5 cities across the nation were contaminated with S. aureus. It also reported that 52% of the bacteria were resistant to at least 3 ...

ByEMSL Analytical, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT